WARNING LETTER

Wilson Livestock MARCS-CMS 728168 — July 24, 2026

Delivery Method:: VIA UPS
Product:: Animal & Veterinary
Drugs
Food & Beverages

Recipient:: Recipient Name

Robert W. Wilson; Recipient Title

Owner; Wilson Livestock; 8983 Red Boiling Springs Rd
Lafayette, TN 37150
United States; wilson.livestock@yahoo.com

Issuing Office:: Center for Veterinary Medicine; United States

WARNING LETTER
CMS # 728168

July 24, 2026

Dear Robert Wilson,

The U.S. Food and Drug Administration (FDA) conducted a compliance follow-up inspection of your livestock dealing operation, located at 8983 Red Boiling Springs Rd, Lafayette, TN 37150, from January 22 through March 11, 2026. This letter notifies you of the significant violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) that we found during our inspection of your operation. You can find the FD&C Act and its associated regulations on the internet through links on FDA’s web page at www.fda.gov.

At the close of the inspection, you were issued a Form FDA 483, Inspectional Observations (FDA 483). We have not received a written response to the FDA 483 as of the date of this letter.

Adulteration of Animals Offered for Human Consumption

Our inspection found you offered animals for sale for slaughter as food that were adulterated. Specifically, you sold the following animals for slaughter as food:

You sold a heifer identified with backtag “(b)(4)” on or about (b)(4). This animal was slaughtered on or about (b)(4), at the (b)(4) in (b)(4). The United States Department of Agriculture/Food Safety and Inspection Service (USDA/FSIS) analysis of tissue samples collected from the animal identified the presence of desfuroylceftiofur at 0.961 parts per million (ppm) in kidney tissue. FDA has established a tolerance of 0.4 ppm of desfuroylceftiofur in the kidney tissue of cattle¹.

The presence of this drug in the edible tissues of this animal at this level causes the food to be adulterated. A food is deemed to be adulterated if it bears or contains a new animal drug that is unsafe.² A drug is unsafe if it results in any residues that exceed any established safe levels.³ The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act.⁴

Additionally, our inspection found that you hold animals under conditions that are inadequate such that medicated animals bearing potentially harmful drug residues are likely to enter the food supply. Specifically, you did not maintain treatment records for drugs administered to cattle on your farm. Food held under conditions whereby it may have been rendered injurious to health is adulterated.⁵

Adulteration of a New Animal Drug

Our inspection found you did not use (b)(4) as directed by its approved labeling. Use of a drug in a manner that is not consistent with its labeling is extralabel use.⁶

The extralabel use of approved animal or human drugs in animals is allowed under the FD&C Act only if the extralabel use complies with section 512(a)(4) and (5) of the FD&C Act [21 U.S.C. 360b(a)(4) and (5)], and 21 CFR Part 530. However, certain drugs are prohibited from extralabel use and are listed in 21 CFR 530.41.

Our inspection found that you administer (b)(4) for disease prevention purposes to all cattle prior to releasing them into your fields. This is not an approved use of the drug under the manufacturer's labeling. Further, the use of this drug for those purposes is prohibited. (b)(4) is a cephalosporin drug that is prohibited from use in food-producing animals for disease prevention purposes under 21 CFR 530.41(a)(13)(i). Because your use of this drug was not in conformance with its approved labeling and did not comply with 21 CFR Part 530, you caused the drug to be unsafe and adulterated.⁷ The introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act.⁸

Conclusion

This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that you comply with all requirements of federal law and FDA regulations.

This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to regulatory, or where appropriate legal action.

Within 15 working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will complete the correction. If you believe you have complied with the FD&C Act and FDA regulations, include your reasoning and any supporting information for our consideration.

The FDA, CVM, Office of Surveillance and Compliance is encouraging electronic submission of any response you choose to submit to this letter. We encourage you to submit files up to 100 megabytes in a single email, and to divide files greater than 100 megabytes so they may be submitted as smaller files in separate emails. If you submit electronic correspondence, please ensure that your facility’s name, the CMS number at the top of this letter, and the inspection location are included in your correspondence. We intend to issue an electronic acknowledgement upon receipt of your email.

If you are unable to submit your correspondence electronically, please direct it to the attention of Christopher Dedeaux, Compliance Officer, at the following address:

United States Food & Drug Administration
Center for Veterinary Medicine
Office of Surveillance and Compliance
Division of Food Compliance
CPK1, 5001 Campus Drive
College Park, Maryland 20740-3835

Please direct your electronic correspondence to Compliance Officer Christopher Dedeaux at Christopher.Dedeaux@fda.hhs.gov. If you have questions regarding this letter, please contact Compliance Officer Christopher Dedeaux by telephone at (504) 846-6122, or by email at Christopher.Dedeaux@fda.hhs.gov.

/S/

Isaac K. Carney
Director of Food Compliance, Office of Surveillance and Compliance
Center for Veterinary Medicine
U.S. Food and Drug Administration

cc:
Janet McGinn, Director
Division of Dairy Safety
Office of Dairy and Seafood Safety
Human Foods Program
Janet.Mcginn@fda.hhs.gov

______________________

1 See 21 CFR 556.113(b)(1)(i).

2 See Section 402(a)(2)(C)(ii) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 342(a)(2)(C)(ii)].

3 See Section 512(a)(4)(B) of the FD&C Act [21 U.S.C. § 360b(a)(4)(B)].

4 See Section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].

5 See Section 402(a)(4) of the FD&C Act [21 U.S.C. § 342(a)(4)].

6 See 21 CFR 530.3(a).

7 Under Section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)], a new animal drug is deemed adulterated if it is unsafe within the meaning of Section 512 of the FD&C Act [21 U.S.C. § 360b].

8 See Section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].